US 12,186,335 B2
Methods and compositions for inhibiting enveloped viruses using high molecular weight hydrophobically modified alkali swellable emulsion polymers and surfactant
Elizabeth Bruning, Skillman, NJ (US); Anthony Robert Geonnotti, III, Skillman, NJ (US); Euen Thomas Ekman-Gunn, Skillman, NJ (US); Russel Walters, Skillman, NJ (US); Alpana Oak, Skillman, NJ (US); Frank C. Sun, Skillman, NJ (US); Kimberly Capone, Skillman, NJ (US); and Frank J. Kirchner, Skillman, NJ (US)
Assigned to Johnson & Johnson Consumer Inc., Skillman, NJ (US)
Filed by Johnson & Johnson Consumer Inc., Skillman, NJ (US)
Filed on Apr. 23, 2020, as Appl. No. 16/856,861.
Prior Publication US 2021/0330701 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/78 (2006.01); A61K 9/00 (2006.01); A61K 31/085 (2006.01); A61P 31/18 (2006.01)
CPC A61K 31/78 (2013.01) [A61K 9/0014 (2013.01); A61K 31/085 (2013.01); A61P 31/18 (2018.01)] 12 Claims
 
1. A method of inhibiting entry of enveloped viruses into cells comprising contacting said viruses with an anti-viral composition comprising at least one hydrophobically modified polymer having a number average molecular weight (Mn) of more than 100,000 as measured by gel permeation chromatography (GPC) calibrated with a poly(methyl methacrylate) (PMMA) standard,
wherein the hydrophobically modified polymer is a hydrophobically modified alkali swellable emulsion polymer, which is polyacrylate-33,
wherein the amount of said hydrophobically modified polymer is from about 0.00005% to about 3% by weight of the anti-viral composition,
wherein the anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12,
wherein said contacting is done by applying the anti-viral composition to skin or mucosal tissue of a subject,
wherein the formulated anti-viral composition, upon application that contacts the enveloped viruses, inhibits entry of the enveloped viruses into cells, and
wherein the enveloped virus is human immunodeficiency virus type 1 (HIV-1).